ライフサイエンスコーパス: follow up

1 rolled 5823 patients within 1 year (with 98% follow-up).

2 ut diabetic retinopathy (DR) after 1 year of follow-up.

3 hundred ninety-five (93%) completed 12-week follow-up.

4 -unclassified with 24,543.0 patient-years of follow-up.

5 verse events either immediately or at 2-week follow-up.

6 asthma history with obesity incidence during follow-up.

7 index endoscopy and after 1 year or more of follow-up.

8 imensions health survey at baseline and over follow-up.

9 NSAIDs at baseline and death information at follow-up.

10 1 January 2000 and had at least 12 months of follow-up.

11 nal prospective cohort study over 5 years of follow-up.

12 myeloid neoplasms after at least 5 years of follow-up.

13 order (PHQ-9 score >/=10) at 4- and 12-month follow-up.

14 improvements in symptom severity at 3-month follow-up.

15 t this needs to be confirmed at the 18 month follow-up.

16 ing outcomes in 985 patients during a 5-year follow-up.

17 stroke, which developed between baseline and follow-up.

18 ive EGFR-TKI after WBRT/SRS, or insufficient follow-up.

19 y were performed at regular intervals during follow-up.

20 ron through R2* map at 24-72 h and at 1-year follow-up.

21 onitoring, and polysomnography at the end of follow-up.

22 ke, or repeat revascularization at long-term follow-up.

23 245 with contralateral breast cancer during follow-up.

24 8 incident cases of vitiligo over 2 years of follow-up.

25 stic factors related to IBTR using long-term follow-up.

26 or noninvasively the patients' status during follow-up.

27 ucose level (beta=131; 95% CI 38-225) during follow-up.

28 ), respectively, over a total of 20 years of follow-up.

29 x patients (12.9%) developed a cancer during follow-up.

30 r significantly in age, race, or duration of follow-up.

31 P < 0.001 and P = 0.02, respectively) during follow-up.

32 er parasite clearance and three were lost to follow-up.

33 secondary prophylaxis and/or regular medical follow-up.

34 y secondary outcome at 4 weeks or the end of follow-up.

35 with a subsequent 4-wk WS period and a 9-mo follow-up.

36 the most desired interventions to facilitate follow-up.

37 t-corrected visual acuity (BCVA) at 6 months follow-up.

38 NAFLD patients with 17,452 patient years of follow-up.

39 subject to attrition bias caused by passive follow-up.

40 essive subtype that warrants closer clinical follow-up.

41 evaluated; at the 1-year, 2-year, and 4-year follow-up 11, 10, and 7 eyes were evaluated, respectivel

42 hern Sweden were included (7121 deaths; mean follow-up: 13.7 y).

43 In HD8 (N = 1,064; median follow-up, 153 months), noninferiority of involved-field

44 During 1,190,170 person-years of follow-up (1982-2012), there was no association between

45 During 873,376 person-years of follow-up (1990-2012), longer durations of NSAID use (fo

46 During follow-up, 2,329 MM cases occurred.

47 Results Over an average of 7.2 years of follow-up (2004 to 2011), 2,407 first primary breast can

48 During 2-year follow-up, 29 (13.6%) patients developed VTE.

49 nts) and were followed for 48 weeks (loss to follow-up, 3.1%).

50 During a 13-year follow-up, 33 (67%) participants died.

51 ast 18 months after the procedure (mean [SD] follow-up, 33 [14] months).

52 During approximately 7 y of follow-up, 372 CVD deaths and 249 IHD deaths occurred.

53 of diabetes risk.In 494,741 person-years of follow-up, 5207 participants developed T2DM.

54 During the subsequent 11.4 years (mean) of follow-up, 566 incident endometrial cancer occurrences w

55 e followed up during the study period (total follow-up, 57.1 million person-years).

56 During follow-up, 62 strokes or TIAs, 42 myocardial infarctions

57 During 7 y of follow-up, 9,504 new diabetes cases were recorded among

58 In HD10 (N = 1,190; median follow-up, 98 months), noninferiority of two cycles of d

59 Fourteen patients completing 12 weeks of follow-up achieved a sustained virological response.

60 antly decreased from pretest to posttest and follow-up after recall+EMs relative to the control condi

61 Median follow-up after transplantation was 6.6 years (379 patie

62 At the 6-month follow-up all eyes were evaluated; at the 1-year, 2-year

63 After nearly 20 years of follow-up among men with localized prostate cancer, surg

64 of geographic atrophy (GA) during 5 years of follow-up among participants in the Comparison of Age-Re

65 Follow-up analyses revealed significant subgrouping effe

66 risingly appeared to extend past 10 years of follow-up and include cancers at distant anatomical site

67 flet thrombosis was detected in 1 patient at follow-up and resolved after increased oral anticoagulat

68 h eGFR slope were selected as candidates for follow-up and secondarily tested for association with pr

69 ry outcomes were the PHQ-9 score at 12-month follow-up and the proportion meeting criteria for depres

70 erall, 65 936 of the full sample died during follow-up, and 22 152 died from heart disease.

71 re fully informed and consent, can adhere to follow-up, and alert providers to hepatitis symptoms.

72 ally proven appendicitis and 6-week clinical follow-up as diagnostic reference standards.

73 breast cancer by using histologic or imaging follow-up as the standard of reference.

74 emales [50%]) who had sufficient data at the follow-up assessment for inclusion in this study.

75 p, dosage-finding, 26-week trial with 5-week follow-up at 100 sites (hospital clinics, general practi

76 Median follow-up at the end of the trial on Nov 5, 2014, was 49

77 Infants were followed up at ages 6 (n = 2956) and 12 (n = 2872) month

78 These subjects were followed up at least for 12 months.

79 a large treatment gap (pre-treatment loss to follow-up) between the numbers of patients with laborato

80 ive recipients turned C4d-negative in 5-week follow-up biopsies, while another 2 recipients showed a

81 Twenty-two follow-up blood samples were collected in BD patients.

82 current asthma was ultimately ruled out were followed up clinically with repeated bronchial challenge

83 s and telephone interviews at eight waves of follow-up, commencing at mean age 15.9 years (SD 0.5; wa

84 of treated patients survived to 18 months of follow-up, compared with untreated controls (P < .001).

85 fewer subsequent hospitalizations and lower follow-up costs.

86 dvanced right-sided lesions were detected at follow-up CT colonography, many of which were flat, serr

87 We used prospective follow-up data from the UK Biobank cohort study to asses

88 A total of 142 participants had follow-up data in both treatment periods.

89 ials in adolescents with at least 5 years of follow-up data that capture financial and quality-of-lif

90 y, bronchodilator reversibility, and FeNO at follow-up; data for peak expiratory flow variability wer

91 wed until their first CHF event, death, last follow-up date, or December 31, 2011.

92 t surgery, the time to the last visit of the follow-up, date of death, or the end of the study.

93 sustained, modest decrease in LVEF over the follow-up duration (1-year change in LVEF -3.6%; 95% con

94 had 2-16 assessment waves (median = 3) and a follow-up duration of 2-15 y.

95 At the data cutoff, median follow-up duration was 11.0 months (range, 1.3 to 32.2 m

96 Total follow-up duration was up to 7.9 years, and median follo

97 with differences in study design, location, follow-up duration, and vaccine composition posing chall

98 duals born in Denmark from 1955 to 2012 were followed up during the study period (total follow-up, 57

99 were categorized with improved eGFR (30-day follow-up eGFR>/=10% higher than baseline pre-TAVR), wor

100 A longer follow-up evaluation is required to accurately describe

101 n with surgery with visual symptom scales at follow-up evaluations ranged from r = 0.24 to r = 0.49.

102 patients received multidisciplinary medical follow-up expected to last at least 1 year that included

103 ore for events encountered during the entire follow-up experience for each patient.

104 Mortality follow-up extended up to 18 months after this period.

105 240 days after enrolment and 12 died during follow-up (five in the intervention group; seven in the

106 planned 1100 patients had been enrolled with follow-up for a median of 15 months.

107 time to recurrence was 14 months, and median follow-up for control subjects was 102 months.

108 tandardized diagnostic routines and a better follow-up for LNB patients.

109 socioeconomic intervention, of whom 231 were followed up for 1 year.

110 Participants were followed up for 12.5 years, with 57 incident CHD events

111 ation Trust in London, UK, 245 patients were followed up for 2 years from the onset of first-episode

112 Patients were followed up for 2.3+/-1.1 years.

113 ir) twice a day for 5-10 days; patients were followed up for 28 days.

114 5 days, given orally, and participants were followed up for 28 days.

115 ore the transplant surgery and patients were followed up for 6 months.

116 Glaucoma patients were followed up for a mean of 3.90 years (range, 2.03-5.44 y

117 started at age 1 year, and the children were followed up for as long as 10.7 years (median, 5.5 years

118 ed for physical and psychiatric problems and followed up for one year from adjustment of their treatm

119 for celiac disease and type 1 diabetes were followed up for up to 20 years for development of tissue

120 All participants were followed-up for medically certified cardiac events from

121 e followed from 1985 to 2009, and the median follow-up from baseline to CRC diagnosis was 8.2 y.

122 solid FI episode per month during 4 years of follow-up from self-administered, biennial questionnaire

123 , prospective design, and virtually complete follow-up; however, histologic details were missing for

124 uction in all-cause mortality at 12 years of follow-up (HR, 0.79 [95% CI, 0.69-0.91]; P=0.001), and t

125 dmission for heart failure decompensation in follow-up (HR, 1.66; 95% CI, 1.27-2.18; P < .001).

126 cted for TAMK or TTIL completed baseline and follow-up HRQL assessments for up to 24 months using the

127 ratio for overall survival in patients with follow-up HSCT (inotuzumab ozogamicin vs standard care)

128 Regular follow-up imaging studies should avoid the use of CT/ang

129 vement in NEI-VFQ-25 scores after 3 years of follow-up (implant: 11.9 points; 95% confidence interval

130 Median (range) follow-up in 68 adults (median [range] age, 66 [48-83] y

131 Partial recurrence was observed during follow-up in a patient treated for 6 months.

132 sess predictors of exacerbation count during follow-up in all patients with available data.

133 leb morphology or function after one year of follow-up in eyes following previous successful trabecul

134 Phenotypic follow-up in five individuals with GRIA1 mutations shows

135 rchitecture of cardiac structure and warrant follow-up in future functional studies.

136 Over up to 15 years of follow-up in the Bruneck Study, multivariable adjusted r

137 , which were maintained at the end of 1 year follow-up in these five patients.

138 ted with lower risk of distant metastases at follow-up in univariate analysis (Log-rank P = 0.0084) b

139 39% moderate, and 12% complex) prospectively followed up in a tertiary center for 37 607 person-years

140 Follow-up included 3-day Holter ECG recordings and offic

141 s were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 perso

142 /- 8.1, and 28.9 +/- 7 degrees at 2 years of follow-up, indicating angle narrowing of 39%-45% and no

143 istory at enrollment in 1993-1997 and in 5-y follow-up interviews.

144 ce rate is higher, and vigilant and extended follow-up is needed because retinal vascularization is u

145 Longer term follow-up is needed to assess the durability of quality-

146 Recruitment has ended, but follow-up is ongoing.

147 Continued follow-up is warranted.

148 During follow-up (mean = 6.4 years), 1,843 invasive breast canc

149 Follow-up measures were the PTSD Checklist-Civilian Vers

150 Readers evaluated baseline and follow-up morphology on digital color images, fluorescei

151 mortality, retrograde type A dissection and follow-up mortality appeared lower.

152 raphy because of radiologic deterioration at follow-up MR imaging between 2006 and 2015.

153 with an episode of MDD that had remitted by follow-up (n = 4), and offspring with missing baseline M

154 f the frontocentral cortices during rest and follow-up neural and behavioral effects of cognitive dis

155 By the end of 1 year follow-up, normalisation of serum aminotransferases occu

156 Follow-up occurred on days 5, 6, 12, 35, and 150 postran

157 rolled, randomized trial (July 2013 to final follow-up October 2014) conducted in 54 family practices

158 Longitudinal follow up of birth cohorts in diverse environments world

159 We included RCTs with a follow-up of >/=3 wk that assessed the effect of KJM on

160 During a mean follow-up of 11.3 +/- 9.4 years, the predominant arrhyth

161 or IVCM examination that were excised and on follow-up of 12 months or longer for the remaining 140 l

162 After a median follow-up of 13 years, 1 or more ODHs were detected in 1

163 At median follow-up of 15.6 months, progression-free survival (PFS

164 During a mean follow-up of 16.6 years, 31.7% of participants developed

165 At the latest median follow-up of 19 months, there was 100% (death-censored)

166 HF cases, 952 deaths occurred over a median follow-up of 2.3 years.

167 Two hundred ninety-seven eyes with a median follow-up of 2.6 years were included.

168 At a median follow-up of 2.8 years (range, 0.03-12.8 years), 1090 pa

169 stable angina hospitalizations over a median follow-up of 26.1 months.

170 During a median follow-up of 27 months (IQR: 6 to 62 months), 50% of gro

171 During a mean follow-up of 3.9+/-2.4 years, the primary end point of d

172 At a median follow-up of 36 months, the study reveals no differences

173 Over a median follow-up of 4.0 years, 340 participants died.

174 from 104 patients were included with a mean follow-up of 5.0 years (interquartile range [IQR] 1.6-7.

175 During a median follow-up of 5.0 years (interquartile range, 3.5-6.0 yea

176 After a mean follow-up of 5.9 years (range, 3.2-10.1 years), 1203 inc

177 After a mean (SD) follow-up of 6.4 (2.5) years, RV outflow tract dimension

178 During a median follow-up of 6.8 years, 256 recipients died, 35 (13.7%)

179 estimated survival 57 +/- 13%) with a median follow-up of 65 months (minimum 38 months).

180 ed for analysis, 1600 died during the median follow-up of 7.1 years.

181 Results At a median follow-up of 7.4 years, addition of rituximab to chloram

182 After a median follow-up of 79 months, 86 patients had discontinued rux

183 FR was 94 ml/min per 1.73 m(2) Over a median follow-up of 8 years, 228 (6.4%) cases of incident CKD o

184 During a mean follow-up of 9.2 years, 552 deaths were observed, of whi

185 Longitudinal follow-up of clinical measures and DAT imaging occurred

186 roach provides a quantitative spatiotemporal follow-up of disease course in relation to clinical mani

187 e- and postoperative examinations during the follow-up of included uncorrected and spectacle correcte

188 sts the biological importance of optogenetic follow-up of less-publicized electrical stimulation find

189 reakthrough in the diagnosis, treatment, and follow-up of many ocular diseases, especially retinal an

190 Also, long-term follow-up of patients with TTP is crucial to identify th

191 lusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the favorable out

192 The 5-year follow-up of the TWENTE participants was prespecified in

193 P-selectin may be used to improve diagnosis, follow-up of treatment, and management of relapse/remiss

194 ignificantly increased, even after long-term follow-up of up to 20 years.

195 We followed up on this finding in a larger dimensional ACQ

196 ore the genetics in a larger set of patients following-up on the most promising genomic regions previ

197 had cysts </=1.5 cm for more than 5 years of follow-up; only 1 of these patients (0.9%) developed a d

198 al noninfectious etiology or lack of further follow-up or details regarding the antibiotic treatment.

199 At 5-year follow-up, overall survival was improved among patients

200 In this follow-up paper to our previous work on single analyzer

201 We followed up participants with HIV from the Veterans Agin

202 After 8 years of follow-up, participants with baseline concentrations of

203 At baseline and follow-up, patient-reported global AD severity significa

204 It is recommended to follow up patients in an HAE comprehensive care center.

205 At 1 year of follow-up, patients from the intervention group (n = 168

206 lowing myopia progression over a twelve-year follow-up period and demonstrated a clinically acceptabl

207 The mean follow-up period for incident events was 12.5 years, fro

208 atients was -0.12+/-0.51 dB/year over a mean follow-up period of 10.4+/-3.7 years.

209 by food-frequency questionnaire.Over a mean follow-up period of 12.4 y, 3259 (31%) deaths occurred.

210 Over a follow-up period of 48 weeks, 37 patients remained absti

211 During the follow-up period, 154 patients (5.7%) developed HGD or E

212 383 children who returned for the full 12-mo follow-up period, 407 children (56%) and 347 children (5

213 During the follow-up period, the magnitude of change in 6MWD differ

214 y signals were observed during the long-term follow-up period.

215 ability in perceived stress during a 4-month follow-up period.

216 nd ASCVD prognostic indicators during a long follow-up period.

217 ized at the time of diagnosis and during the follow-up period.

218 iably characterized in recipient plasma over follow-up periods of up to 5 years.

219 during the 12-week intervention and 3-month follow-up periods.

220 0-0.50) and remained at 20/30 throughout all follow-up periods.

221 tionalities like triflates and mesylates for follow-up reactions as well as the comparison of differe

222 druse developed GA after 24 and 62 months of follow-up, respectively.

223 variables obtained at baseline and at first follow-up RHC.

224 Results After a median of 10.8 years of follow-up since diagnosis, 381 deaths (100 as a result o

225 Follow-up started at age 1 year, and the children were f

226 Upon completion of follow-up studies, we developed the working model that s

227 rning and highlight the need for longer-term follow-up studies.

228 and 41,526 men from the Health Professionals Follow-Up Study (1986 to 2012) who were free of cancer,

229 In conclusion, this follow-up study demonstrated circulating plasma exosomal

230 A follow-up study examined the effects of CAPs exposure du

231 cinoma (ESCC) in Han Chinese, we conducted a follow-up study to examine the single nucleotide polymor

232 We used data from the Gulf Long-term Follow-up Study, a cohort of workers and volunteers invo

233 A prospective follow-up study.

234 through December 31, 2009, and enrolled in a follow-up substudy a mean (SD) of 10 (3) months after th

235 A longitudinal analysis with 2-year follow-up suggested that persistence of MOG-IgG is assoc

236 available had seizures in their last year of follow-up, suggesting enduring seizure control was not r

237 A follow-up survey was performed in 2013 (postdisaster), a

238 tumor registries and who completed a 15-year follow-up survey.

239 At the date of the last follow-up, the differences in visual outcomes between th

240 rom January 1 through December 31, 2011, and followed up through hospitalization.

241 ularization, as well, were recorded during a follow-up time of 7.8+/-2.2 years after the second CT.

242 The median follow-up time was 82 months (range, 6-329 months) for t

243 The median (interquartile range) follow-up time was 9.1 (5.1-12.6) years and 8.1 (4.5-11.

244 Study sample size, patient age, follow-up time, timing of MRD assessment (postinduction

245 All SIRs decreased steeply in the course of follow-up time.

246 are workers must strive to adapt bereavement follow-up to each individual situation.

247 the stroke-affected gastrocnemius) and were followed up to poststroke d 14.

248 At follow-up, triage patients had lower health-related qual

249 ecialist bedside swallowing examinations and follow-up until hospital discharge.

250 Patients were followed up until death or were censored on December 31,

251 Subsequently, participants were followed up until January 1, 2015, for the onset of park

252 ermine if nGA was present at baseline and at follow-up using high-density Spectralis OCT B-scans and

253 ) were measured after doses 1 and 8, then 1 (follow-up visit [FUV] 1) and 3 (FUV2) weeks after final

254 The final follow-up visit was on August 15, 2017.

255 and rate of strabismus and nystagmus at last follow-up visit were calculated.

256 At the 6-month follow-up visit, TRS score was measured, and mood and ps

257 alyzed subjects with more than 4 semi-annual follow-up visits (every 6 months) in the multicenter Adv

258 e services were extracted at the initial and follow-up visits between 2007 and 2014.

259 ion) from treatment (enrollment) and 6-month follow-up visits in 77 women previously classified as ha

260 n total, 35.6% of 1624 children who attended follow-up visits required at least one hospitalization b

261 nt time points during the first and the last follow-up visits.

262 d tested 130 seminal fluid specimens; median follow up was 197 days (IQR 187-209 days) after enrolmen

263 Mean follow-up was 15.1 months (range, 6-22 months).

264 Median follow-up was 15.9 months (IQR 7.8-22.0) at the data cut

265 Median follow-up was 173 days (interquartile range: 54 to 342 d

266 Median follow-up was 23.2 months (IQR 14.8-28.7).

267 The mean follow-up was 27 years.

268 Median follow-up was 28.0 months (IQR 14.6-36.6).

269 -up duration was up to 7.9 years, and median follow-up was 3.1 years.

270 h OA-MCL were reviewed; the median length of follow-up was 33 months.

271 The mean (SD) age at end of follow-up was 4.6 (0.40) years for the 61359 children in

272 The median follow-up was 40 months.

273 The mean (SD) length of follow-up was 40.8 (22.2) months.

274 Median follow-up was 43 months (interquartile range 35-47).

275 he probability of interval CRC by the end of follow-up was 7.1% in black persons and 5.8% in white pe

276 The average time of follow-up was 7.3 years.

277 Median follow-up was 8.6 (range, 0.2-37) years.

278 Follow-up was 83 months.

279 At the time of analysis, the median follow-up was 84 months (range, 1 to 119 months).

280 Median follow-up was 9.1 years (range 5.1 -21.2 yrs).

281 n age was 77 years (range 62-92), and median follow-up was 953 days (IQR 721-1040).

282 Spherical regression at last follow-up was an average of +0.59 D.

283 Final follow-up was August 2012.

284 Echocardiographic follow-up was available in 10 survivors with and 16 with

285 ong patients whose only top diagnosis during follow-up was bvFTD.

286 from January 7, 2011, to September 30, 2014, follow-up was conducted at 30 days and 6 months, and fin

287 Long-term follow-up was included in the third protocol amendment;

288 The data cutoff for follow-up was May 26, 2015.

289 conducted at 30 days and 6 months, and final follow-up was on June 16, 2015.

290 Fluoroscopy and computed tomography follow-up was performed after filter deployment from wee

291 A 6-year follow-up was undertaken from January 7, 2013, through M

292 During follow-up, we identified 5,462 incident cases of rosacea

293 Changes in BMI between baseline and 12 weeks follow-up were assessed in 28 excess-weight participants

294 Still, the detection frequencies at follow-up were for most agents as high as at baseline, b

295 patients (308 patients [96.9%] of whom were followed up) were older and had more advanced disease th

296 cted more eyes in the first 5 years of their follow-up, which were presumably undergoing more rapid p

297 o ask their doctor significantly improved at follow-up while control arm patients' self-efficacy decl

298 FBT on all outcomes at 6-, 12-, and 18-month follow-up with a mean difference in child weight loss of

299 between serum potassium values collected at follow-up with all-cause mortality in a prospective and

300 observation unit and presence of outpatient follow-up within 7 days were associated with a lower odd